Shkreli Quits as Head of Turing Pharmaceuticals
The 32-year-old was arrested on charges related to his prior work as a hedge fund manager.
(
AP photo by Craig Ruttle)
Martin Shkreli has resigned as the head of Turing Pharmaceuticals after being arrested yesterday in connection with his work as a hedge fund manager, the company said in a statement.
Shkreli, 32, became one of the most famous, and scorned, figures in the pharmaceutical business when he got control of Daraprim, an old HIV therapy. Once just $13.50 a pill, Shkreli quickly
Ron Tilles, chairman of the board of Turing, will take over as interim chief executive.
“We wish to thank Martin for helping us build Turing Pharmaceuticals into the dynamic research focused company it is today, and wish him the best in his future endeavors. At the same time, I am very excited about the opportunity to guide Turing Pharmaceuticals forward," Tilles said in the statement.
Shkreli was released on $5 million bail following his
Meanwhile, pharmacy benefit managers moved quickly to ensure patients that they would work to keep supplies of Daraprim available.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- Promising Early Efgartigimod Response Data for Generalized Myasthenia Gravis
September 18th 2025
- Metabolic Issues More Common in Patients With HIV
September 18th 2025
- Barriers to Gender-Affirming Surgery Persist Despite High Satisfaction Rate
September 18th 2025
- Eating Behaviors May Predict GLP-1 Therapy Success in Type 2 Diabetes
September 18th 2025